TOBAM’s 10x Genomics TXG Stock Holding History

TOBAM’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-159,729	Closed	-$23.8M	–	477
2021 Q4	$23.8M	Sell	159,729 -31,575	-17%	-$4.84M	1.07%	33
2021 Q3	$27.9M	Buy	191,304 +5,249	+3%	+$901K	1.18%	37
2021 Q2	$36.4M	Sell	186,055 -25,486	-12%	-$4.61M	1.46%	26
2021 Q1	$38.3M	Buy	211,541 +133,326	+170%	+$23M	1.63%	18
2020 Q4	$11.1M	Buy	+78,215	New	+$11.4M	0.49%	63

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TOBAM's TXG Position: Q1 2022 in Review

TOBAM sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 159,729 shares — an estimated $23.8M sold.

TOBAM first reported a position in TXG in Q4 2020 and held it in 5 quarters. The position peaked at $38.3M in Q1 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

TOBAM reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
TOBAM sold 159,729 10x Genomics shares in Q1 2022, an estimated $23.8M.
TOBAM first reported a position in 10x Genomics in Q4 2020 and held it in 5 quarters.
TOBAM's 10x Genomics position peaked at $38.3M in Q1 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on TOBAM's 13F filing for Q1 2022, filed 25 Apr 2022.